Evolent Health (EVH) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Q1 2026 earnings scheduled May 7 (after market close) — analysts expect EPS of ($0.05) and revenue of $534.02 million, with the company's earnings call set for May 7 at 8:00 AM ET.
• In the last quarter (Feb. 24) Evolent posted EPS of $0.08 (beating estimates) but revenue fell 27.5% year‑over‑year to $468.72 million and the company reported a negative net margin of 28.49%; analysts forecast $0 EPS for the current and next fiscal year.
• Shares trade around $3.78 with a $421.4M market cap; Wall Street's consensus is a "Moderate Buy" with an average target price of $6.04 (13 Buys, 3 Holds, 1 Sell), indicating potential upside from current levels.

Evolent Health (NYSE:EVH - Get Free Report) is anticipated to issue its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $534.0210 million for the quarter. Parties may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:00 AM ET.

Evolent Health (NYSE:EVH - Get Free Report) last announced its quarterly earnings results on Tuesday, February 24th. The technology company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.02. Evolent Health had a positive return on equity of 1.49% and a negative net margin of 28.49%.The business had revenue of $468.72 million during the quarter, compared to analyst estimates of $468.48 million. During the same period in the previous year, the company earned ($0.02) EPS. The firm's revenue was down 27.5% on a year-over-year basis. On average, analysts expect Evolent Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Evolent Health Price Performance

Shares of NYSE:EVH opened at $3.78 on Thursday. The business has a 50-day moving average of $2.83 and a two-hundred day moving average of $3.93. The company has a debt-to-equity ratio of 2.34, a current ratio of 1.31 and a quick ratio of 1.31. Evolent Health has a fifty-two week low of $2.10 and a fifty-two week high of $12.06. The stock has a market capitalization of $421.44 million, a P/E ratio of -0.73 and a beta of 0.37.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Weiss Ratings reissued a "sell (e+)" rating on shares of Evolent Health in a research note on Friday, March 27th. UBS Group lowered their price objective on shares of Evolent Health from $10.00 to $5.00 and set a "buy" rating on the stock in a research note on Thursday, February 26th. KeyCorp downgraded shares of Evolent Health from an "overweight" rating to a "sector weight" rating in a research note on Wednesday, February 25th. BTIG Research lowered their price objective on shares of Evolent Health from $10.00 to $8.00 and set a "buy" rating on the stock in a research note on Wednesday, February 25th. Finally, Citigroup lowered their price objective on shares of Evolent Health from $6.00 to $4.00 and set a "buy" rating on the stock in a research note on Thursday, February 26th. Thirteen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $6.04.

Hedge Funds Weigh In On Evolent Health

A number of institutional investors and hedge funds have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Evolent Health by 2.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 128,527 shares of the technology company's stock worth $1,217,000 after purchasing an additional 3,572 shares in the last quarter. CIBC Private Wealth Group LLC boosted its stake in Evolent Health by 4,000.0% in the third quarter. CIBC Private Wealth Group LLC now owns 4,100 shares of the technology company's stock worth $35,000 after purchasing an additional 4,000 shares in the last quarter. Strs Ohio acquired a new position in Evolent Health in the first quarter worth $47,000. Headlands Technologies LLC acquired a new position in Evolent Health in the second quarter worth $58,000. Finally, Osaic Holdings Inc. boosted its stake in Evolent Health by 99.2% in the second quarter. Osaic Holdings Inc. now owns 11,119 shares of the technology company's stock worth $125,000 after purchasing an additional 5,537 shares in the last quarter.

Evolent Health Company Profile

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company's core offerings include care management solutions, population health analytics and clinical advisory services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.